Culture models to define key mediators of cancer matrix remodeling

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Fuller, Emily Suzanne ^a   Howell, Viive Maarika ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

3D; Culture models; High grade serous epithelial ovarian cancer; Metastasis; Synthetic scaffolds

Indexed keywords

ALGINIC ACID; COLLAGEN GEL; MACROGOL; MATRIGEL; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

AMNION; ARTICLE; CANCER MODEL; CELL ADHESION; CELL CULTURE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CHORIOALLANTOIS; DISEASE COURSE; EXTRACELLULAR MATRIX; HEREDITY; OVARY CARCINOMA;

EID: 84901060897     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00057     Document Type: Article

References (78)

1. Saladino E, Fleres F, Irato S, Famulari C, Macrí A. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse. Updates Surg (2013) 65(4):265-70. doi: 10.1007/s13304-013-0229-9.
2. van Altena AM, van den Akker PA, de Hullu JA, Ottevanger PB, Aalders AL, Gerritse R, et al. Efficacy of a regional network for ovarian cancer care. Obstet Gynecol (2013) 122(3):668-75. doi:10.1097/AOG.0b013e3182a054ee.
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 354(1):34-43. doi:10.1056/NEJMoa052985.
4. Eskander RN, Tewari KS. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol (2013) 5(Suppl 1):55-61. doi:10.2147/CPAA.S45885.
5. Baumann KH, Wagner U, du Bois A. The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol (2012) 8(9):1135-47. doi:10.2217/fon.12.112.
6. Jiang F, Saunders BO, Haller E, Livingston S, Nicosia SV, Bai W. Conditionally immortal ovarian cell lines for investigating the influence of ovarian stroma on the estrogen sensitivity and tumorigenicity of ovarian surface epithelial cells. In vitro Cell Dev Biol Anim (2003) 39(7):304-12. doi:10.1290/1543-706X(2003)039<0304:CIOCLF>2.0.CO;2.
7. Nicosia SV, Nicosia RF. Neoplasms of ovarian mesothelium. In: Azar HA, Azar HA, editors. Pathology of Human Neoplasms. New York: Raven Press (1988). p. 435-86.
8. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4:2126. doi:10.1038/ncomms3126.
9. Jones PM, Drapkin R. Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms. Front Oncol (2013) 3:217. doi:10.3389/fonc.2013.00217.
10. Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc (2012) 7(9):1755-64. doi:10.1038/nprot.2012.097.
11. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A (2011) 108(18):7547-52. doi:10.1073/pnas.1017300108.
12. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A (2012) 109(10):3921-6. doi:10.1073/pnas.1117135109.
13. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 34(3):433-43. doi:10.1097/PAS.0b013e3181cf3d79.
14. Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, Pensabene M. New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int (2013) 2013:852839. doi:10.1155/2013/852839.
15. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS One (2013) 8(9):e72162. doi:10.1371/journal.pone.0072162.
16. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 108(46):18708-13. doi:10.1073/pnas.1111840108.
17. Archibald KM, Kulbe H, Kwong J, Chakravarty P, Temple J, Chaplin T, et al. Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene (2012) 31(48):4987-95. doi:10.1038/onc.2011.653.
18. Davies BR, Steele IA, Edmondson RJ, Zwolinski SA, Saretzki G, von Zglinicki T, et al. Immortalisation of human ovarian surface epithelium with telomerase and temperature-sensitive SV40 large T antigen. Exp Cell Res (2003) 288(2):390-402. doi:10.1016/S0014-4827(03)00218-0.
19. Fotheringham S, Levanon K, Drapkin R. Ex vivo culture of primary human fallopian tube epithelial cells. J Vis Exp (2011) (51):e2728. doi:10.3791/2728.
20. Lawrenson K, Sproul D, Grun B, Notaridou M, Benjamin E, Jacobs IJ, et al. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Carcinogenesis (2011) 32(10):1540-9. doi:10.1093/carcin/bgr140.
21. Maeda T, Tashiro H, Katabuchi H, Begum M, Ohtake H, Kiyono T, et al. Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer (2005) 93(1):116-23. doi:10.1038/sj.bjc.6602662.
22. Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest (2013) 93(5):528-42. doi:10.1038/labinvest.2013.41.
23. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 10(2):325-35. doi:10.1158/1535-7163.MCT-10-0788.
24. Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, et al. Ovarian cancer stem cells. Neoplasma (2012) 59(6):747-55. doi:10.4149/neo_2012_094.
25. Infanger DW, Lynch ME, Fischbach C. Engineered culture models for studies of tumor-microenvironment interactions. Annu Rev Biomed Eng (2013) 15:29-53. doi:10.1146/annurev-bioeng-071811-150028.
26. Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle (2009) 8(5):683-8. doi:10.4161/cc.8.5.7703.
27. Kwon Y, Cukierman E, Godwin AK. Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One (2011) 6(4):e18872. doi:10.1371/journal.pone.0018872.
28. Martell RE, Brooks DG, Wang Y, Wilcoxen K. Discovery of novel drugs for promising targets. Clin Ther (2013) 35(9):1271-81. doi:10.1016/j.clinthera.2013.08.005.
29. Sodek KL, Brown TJ, Ringuette MJ. Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration. BMC Cancer (2008) 8:223. doi:10.1186/1471-2407-8-223.
30. Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev (2012) 31(1-2):397-414. doi:10.1007/s10555-012-9351-2.
31. Pouliot N, Pearson HB, Burrows A. Investigating metastasis using in vitro platforms. In: Madame Curie Bioscience Database [Internet]. (2013). Austin, TX: Landes Bioscience; Available from: http://www.ncbi.nlm.nih.gov/books/NBK100379/.
32. Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther (2008) 7(10):3441-51. doi:10.1158/1535-7163.MCT-08-0417.
33. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol (2005) 15(5):378-86. doi:10.1016/j.semcancer.2005.05.004.
34. Cai J, Tang H, Xu L, Wang X, Yang C, Ruan S, et al. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis (2012) 33(1):20-9. doi:10.1093/carcin/bgr230.
35. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 118(4):1367-79. doi:10.1172/JCI33775.
36. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer (2007) 121(7):1463-72. doi:10.1002/ijc.22874.
37. Kusuma N, Anderson RL, Pouliot N. Laminin alpha5-derived peptides modulate the properties of metastatic breast tumour cells. Clin Exp Metastasis (2011) 28(8):909-21. doi:10.1007/s10585-011-9422-8.
38. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol (2006) 103(2):405-16. doi:10.1016/j.ygyno.2006.03.056.
39. Kaimal R, Aljumaily R, Tressel SL, Pradhan RV, Covic L, Kuliopulos A, et al. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res (2013) 73(8):2457-67. doi:10.1158/0008-5472.CAN-12-1426.
40. Moss NM, Liu Y, Johnson JJ, Debiase P, Jones J, Hudson LG, et al. Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol Cancer Res (2009) 7(6):809-20. doi:10.1158/1541-7786.MCR-08-0571.
41. Avraham-Chakim L, Elad D, Zaretsky U, Kloog Y, Jaffa A, Grisaru D. Fluid-flow induced wall shear stress and epithelial ovarian cancer peritoneal spreading. PLoS One (2013) 8(4):e60965. doi:10.1371/journal.pone.0060965.
42. Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, et al. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl Med (2013) 11:28. doi:10.1186/1479-5876-11-28.
43. de Vrij J, Dautzenberg IJ, van den Hengel SK, Magnusson MK, Uil TG, Cramer SJ, et al. A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction. Gene Ther (2012) 19(9):899-906. doi:10.1038/gt.2011.162.
44. Vukicevic S, Kleinman HK, Luyten FP, Roberts AB, Roche NS, Reddi AH. Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res (1992) 202(1):1-8. doi:10.1016/0014-4827(92)90397-Q.
45. Yang Z, Zhao X. A 3D model of ovarian cancer cell lines on peptide nanofiber scaffold to explore the cell-scaffold interaction and chemotherapeutic resistance of anticancer drugs. Int J Nanomedicine (2011) 6:303-10. doi:10.2147/IJN.S15279.
46. Mason BN, Starchenko A, Williams RM, Bonassar LJ, Reinhart-King CA. Tuning three-dimensional collagen matrix stiffness independently of collagen concentration modulates endothelial cell behavior. Acta Biomater (2013) 9(1):4635-44. doi:10.1016/j.actbio.2012.08.007.
47. Raeber GP, Lutolf MP, Hubbell JA. Molecularly engineered PEG hydrogels: a novel model system for proteolytically mediated cell migration. Biophys J (2005) 89(2):1374-88. doi:10.1529/biophysj.104.050682.
48. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials (2010) 31(32):8494-506. doi:10.1016/j.biomaterials.2010.07.064.
49. Azzazene D, Al Thawadi H, Al Farsi H, Besbes S, Geyl C, Mirshahi S, et al. Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells. Int J Oncol (2013) 43(4):1011-8. doi:10.3892/ijo.2013.2021.
50. Giuntoli RL II, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res (2009) 29(8):2875-84.
51. Govindaraj C, Scalzo-Inguanti K, Madondo M, Hallo J, Flanagan K, Quinn M, et al. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol (2013) 149(1):97-110. doi:10.1016/j.clim.2013.07.003.
52. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 348(3):203-13. doi:10.1056/NEJMoa020177.
53. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 73(16):5016-28. doi:10.1158/0008-5472.CAN-13-0023.
54. Celli JP, Rizvi I, Blanden AR, Massodi I, Glidden MD, Pogue BW, et al. An imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour models. Sci Rep (2014) 4:3751. doi:10.1038/srep03751.
55. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell (2007) 130(4):601-10. doi:10.1016/j.cell.2007.08.006.
56. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol (2010) 148(1):3-15. doi:10.1016/j.jbiotec.2010.01.012.
57. Lawrenson K, Grun B, Gayther SA. Heterotypic three-dimensional in vitro modeling of stromal-epithelial interactions during ovarian cancer initiation and progression. J Vis Exp (2012) (66):e4206. doi:10.3791/4206.
58. Lawrenson K, Notaridou M, Lee N, Benjamin E, Jacobs IJ, Jones C, et al. In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. BMC Cell Biol (2013) 14(1):43. doi:10.1186/1471-2121-14-43.
59. Sutherland ML, Fabre KM, Tagle DA. The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline. Stem Cell Res Ther (2013) 4(Suppl 1). doi:10.1186/scrt361.
60. Wheeler SE, Borenstein JT, Clark AM, Ebrahimkhani MR, Fox IJ, Griffith L, et al. All-human microphysical model of metastasis therapy. Stem Cell Res Ther (2013) 4(Suppl 1). doi:10.1186/scrt372.
61. Barbolina MV, Liu Y, Gurler H, Kim M, Kajdacsy-Balla AA, Rooper L, et al. Matrix rigidity activates Wnt signaling through down-regulation of Dickkopf-1 protein. J Biol Chem (2013) 288(1):141-51. doi:10.1074/jbc.M112.431411.
62. Kennedy A, Dong H, Chen D, Chen WT. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer (2009) 124(1):27-35. doi:10.1002/ijc.23871.
63. Godugu C, Patel AR, Desai U, Andey T, Sams A, Singh M. AlgiMatrix based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One (2013) 8(1):e53708. doi:10.1371/journal.pone.0053708.
64. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci (2012) 37(1):106-26. doi:10.1016/j.progpolymsci.2011.06.003.
65. Rizzi SC, Ehrbar M, Halstenberg S, Raeber GP, Schmoekel HG, Hagenmüller H, et al. Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes. Part II: biofunctional characteristics. Biomacromolecules (2006) 7(11):3019-29. doi:10.1021/bm060504a.
66. Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, et al. Organotypic models of metastasis: a three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res (2009) 149:335-51. doi:10.1007/978-0-387-98094-2_16.
67. Carduner L, Picot CR, Leroy-Dudal J, Blay L, Kellouche S, Carreiras F. Cell cycle arrest or survival signaling through alphav integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. Exp Cell Res (2014) 320(2):329-42. doi:10.1016/j.yexcr.2013.11.011.
68. Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, et al. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One (2013) 8(2):e57056. doi:10.1371/journal.pone.0057056.
69. Grun B, Benjamin E, Sinclair J, Timms JF, Jacobs IJ, Gayther SA, et al. Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif (2009) 42(2):219-28. doi:10.1111/j.1365-2184.2008.00579.x.
70. Soritau O, Tomuleasa CI, Páll E, Virág P, Fischer-Fodor E, Foris V, et al. Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer. Rom J Morphol Embryol (2010) 51(2):259-64.
71. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog (2007) 46(10):872-85. doi:10.1002/mc.20315.
72. Loessner D, Flegg JA, Byrne HM, Clements JA, Hutmacher DW. Growth of confined cancer spheroids: a combined experimental and mathematical modelling approach. Integr Biol (Camb) (2013) 5(3):597-605. doi:10.1039/c3ib20252f.
73. Kunz-Schughart LA, Kreutz M, Knuechel R. Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol (1998) 79(1):1-23. doi:10.1046/j.1365-2613.1998.00051.x.
74. Mueller-Klieser W. Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol (1997) 273(4 Pt 1):C1109-23.
75. Nyga A, Cheema U, Loizidou M. 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal (2011) 5(3):239-48. doi:10.1007/s12079-011-0132-4.
76. Jaeger AA, Das CK, Morgan NY, Pursley RH, McQueen PG, Hall MD, et al. Microfabricated polymeric vessel mimetics for 3-D cancer cell culture. Biomaterials (2013) 34(33):8301-13. doi:10.1016/j.biomaterials.2013.07.013.
77. Baker M. Tissue models: a living system on a chip. Nature (2011) 471(7340):661-5. doi:10.1038/471661a.
78. Young EW. Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment. Integr Biol (Camb) (2013) 5(9):1096-109. doi:10.1039/c3ib40076j.